Zottola v. Eisai Inc.

Background

Barbara Zottola sued Eisai Inc., Arena Pharmaceuticals, Inc., and CVS Pharmacy, Inc., alleging that they knew Belviq and Belviq XR carried an increased cancer risk but failed to disclose that risk. She alleged that Eisai and Arena manufactured and distributed the medications and that she purchased Belviq from CVS after reviewing the labels and disclosures. She sought damages and other relief for herself and proposed nationwide and New York classes.

The complaint asserted claims under New York General Business Law §§ 349 and 350, breach of the implied warranty of merchantability, fraud, fraudulent concealment, unjust enrichment, and conversion. The defendants moved to dismiss under Federal Rule of Civil Procedure 12(b)(6), which allows dismissal when a complaint does not adequately state a legal claim for relief.

New York General Business Law Claims

The court dismissed the claims under §§ 349 and 350. It held that Zottola did not allege a cognizable injury because she alleged only that she would not have purchased the medications if she had known about the cancer risk. She did not allege that the alleged misrepresentations affected the medications’ price or that she or the proposed class members developed cancer or other health problems from using them.

The court also held that the alleged failure to warn about a prescription drug’s risks was not consumer-oriented conduct under New York’s informed-intermediary doctrine. Under that doctrine, the duty to warn runs to the prescribing doctor rather than directly to the patient. The court further found that Zottola did not identify specific misleading statements or explain how particular statements in the labels or disclosures were misleading. The court dismissed both statutory claims and noted that the § 350 claim also failed because Zottola did not identify any advertising.

Conversion

The court dismissed the conversion claim. Zottola alleged that the defendants wrongfully exercised control over money she paid for Belviq, but she did not identify a specific, identifiable fund of money that the defendants had an obligation to return or handle in a particular way. The court also found her allegation that the defendants wrongly exercised control over the money conclusory.

Implied Warranty of Merchantability

The court dismissed the implied-warranty claim against Eisai and Arena because Zottola alleged only economic damages and did not allege that she bought the medications directly from either manufacturer. The court held that New York law required contractual privity—a direct contractual relationship—for an economic-loss warranty claim.

The court also dismissed the claim against CVS. Although Zottola alleged that she purchased Belviq from CVS, the court rejected the proposed theory that a pharmacy could be liable for the manufacturer’s alleged safety defect merely because it filled a prescription.

Fraud and Fraudulent Concealment

The court dismissed the fraud and fraudulent-concealment claims. It again found that Zottola had not alleged a cognizable injury. It also held that the claims failed Federal Rule of Civil Procedure 9(b), which requires fraud to be pleaded with particular detail.

The court found that Zottola did not identify a specific misrepresentation or omission, alleged the defendants’ knowledge and concealment only in conclusory terms, and did not plead facts showing fraudulent intent. The court also found that she did not adequately allege reasonable reliance because she did not identify the information on which she relied, and that she did not allege that the defendants had a duty to disclose the risks directly to her. The opinion also notes that Zottola had conceded that she would pursue these claims only against Eisai and Arena; the court dismissed them as to CVS on that basis as well.

Unjust Enrichment

The court dismissed the unjust-enrichment claim because it relied on the same alleged deceptive conduct as Zottola’s other claims and therefore duplicated those claims. The court held that unjust enrichment could not serve as a substitute for claims that were otherwise inadequately pleaded.

Class Allegations and Leave to Amend

Because the complaint was dismissed in its entirety, the court did not address the defendants’ arguments concerning Zottola’s proposed nationwide class and New York subclass. The court also denied Zottola’s request for leave to amend. It found the request procedurally inadequate because it appeared only as a brief statement in her opposition papers and did not explain how the complaint’s defects could be corrected.

Disposition

Judge Philip M. Halpern granted the defendants’ motion to dismiss the complaint with prejudice, denied Zottola’s request for leave to amend, directed the Clerk to terminate the pending motions, and closed the case.